• van Kempen ZL, Leurs CE, Witte BI, de Vries A, Wattjes MP, Rispens T, Killestein J. The majority of natalizumab-treated MS patients have high natalizumab concentrations at time of re-dosing. Mult Scler. 2017 May 1:1352458517708464.
  • Caldano M, Raoul W, Rispens T, Bertolotto A. Drug Efficacy Monitoring in Pharmacotherapy of Multiple Sclerosis With Biological Agents. Ther Drug Monit. 2017 Aug;39(4):350-355.
  • van Kempen ZL, Leurs CE, Vennegoor A, Wattjes MP, Rispens T, Uitdehaag BM, Killestein J. Natalizumab-associated progressive multifocal leukoencephalopathy is not preceded by elevated drug concentrations. Mult Scler. 2017 Jun;23(7):995-999. doi: 10.1177/1352458516684023.
  • van Schie KA, Kruithof S, van Schouwenburg PA, Vennegoor A, Killestein J, Wolbink G, Rispens T. Neutralizing capacity of monoclonal and polyclonal anti-natalizumab antibodies: The immune response to antibody therapeutics preferentially targets the antigen-binding site. J Allergy Clin Immunol. 2017 Mar;139(3):1035-1037.e6. 
  • Vennegoor A, van Rossum JA, Leurs C, Wattjes MP, Rispens T, Murk JL, Uitdehaag BM, Killestein J.High cumulative JC virus seroconversion rate during long-term use of natalizumab. Eur J Neurol. 2016 Jun;23(6):1079-85.
  • Harrer A, Pilz G, Wipfler P, Oppermann K, Sellner J, Hitzl W, Haschke-Becher E, Afazel S, Rispens T, van der Kleij D, Trinka E, Kraus J. High interindividual variability in the CD4/CD8 T cell ratio and natalizumab concentration levels in the cerebrospinal fluid of patients with multiple sclerosis. Clin Exp Immunol 2015 Jan 20.
  • Vennegoor A, Rispens T, Van Oosten BW, Wattjes MP, Wondergem MJ, Teunissen CE, Van der Kleij D, Uitdehaag B, Polman CH, Killestein J. Application of serum natalizumab levels during plasma exchange in MS patients with progressive multifocal leukoencephalopathy. Mult Scler 2015; 21(4):481-4
  • Vennegoor A, Rispens T, Strijbis EM, Seewann A, Uitdehaag BM, Balk LJ, Barkhof F, Polman CH, Wolbink G, Killestein J.
  • Clinical relevance of serum natalizumab concentration and anti-natalizumab antibodies in multiple sclerosis.  Mult Scler. 2013 Apr;19(5):593-600
  • Rispens T, Vennegoor A, Wolbink GJ, Polman CH, Killestein J. Natalizumab remains detectable in patients with multiple sclerosis long after treatment is stopped. Mult Scler 2012; 18(6):899-901.